Table 2 Baseline characteristics of nab-paclitaxel initiators by line of therapya
Characteristic | First line (n = 172) | Second line (n = 211) | Third line or later (n = 281) | All (N = 664) | ||||
|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Age | ||||||||
≤ 39 y | 4 | 2.3 | 7 | 3.3 | 16 | 5.7 | 27 | 4.1 |
40–49 y | 36 | 20.9 | 53 | 25.1 | 64 | 22.8 | 153 | 23.0 |
50–59 y | 53 | 30.8 | 78 | 37.0 | 116 | 41.3 | 247 | 37.2 |
60–69 y | 58 | 33.7 | 60 | 28.4 | 66 | 23.5 | 184 | 27.7 |
≥ 70 y | 21 | 12.2 | 13 | 6.2 | 19 | 6.8 | 53 | 8.0 |
Geographic area | ||||||||
Midwest | 39 | 22.7 | 47 | 22.3 | 65 | 23.1 | 151 | 22.7 |
Northeast | 12 | 7.0 | 11 | 5.2 | 25 | 8.9 | 48 | 7.2 |
South | 91 | 52.9 | 123 | 58.3 | 146 | 52.0 | 360 | 54.2 |
West | 30 | 17.4 | 30 | 14.2 | 45 | 16.0 | 105 | 15.8 |
Healthcare utilization | ||||||||
No. of physician visits | ||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1–2 | 2 | 1.2 | 2 | 0.9 | 3 | 1.1 | 7 | 1.1 |
≥ 3 | 170 | 98.8 | 209 | 99.1 | 278 | 98.9 | 657 | 98.9 |
No. of emergency department visits | ||||||||
0 | 103 | 59.9 | 117 | 55.5 | 190 | 67.6 | 410 | 61.7 |
1–2 | 51 | 29.7 | 82 | 38.9 | 72 | 25.6 | 205 | 30.9 |
≥ 3 | 18 | 10.5 | 12 | 5.7 | 19 | 6.8 | 49 | 7.4 |
No. of hospitalizations | ||||||||
0 | 119 | 69.2 | 138 | 65.4 | 196 | 69.8 | 453 | 68.2 |
1–2 | 47 | 27.3 | 68 | 32.2 | 77 | 27.4 | 192 | 28.9 |
≥ 3 | 6 | 3.5 | 5 | 2.4 | 8 | 2.8 | 19 | 2.9 |
Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
Length of health plan membership, y | 2.6 | (1.4–4.2) | 1.9 | (1.0–3.0) | 2.7 | (1.7–4.0) | 2.4 | (1.4–3.7) |
Length of inpatient stay, db | 5.0 | (3.0–13.0) | 4.0 | (2.0–9.0) | 5.0 | (2.0–8.0) | 5.0 | (2.0–9.0) |